Company: DMAAR
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-046061
Chunk: 16

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
    Basic net income per ordinary share 
    $0.05  
    $0.05 

    Diluted net income per share: 

    Numerator: 

    Allocation of net income 
    $746,471  
    $508,072 
  
    Denominator: 

    Weighted-average shares outstanding 
     15,177,778  
     10,330,476 
  
    Diluted net income per ordinary share 
    $0.05  
    $0.05 

Recent Accounting Standards  

Management does not believe that any recently
issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial
statement.

NOTE 3 — INITIAL PUBLIC OFFERING

Pursuant to the Initial Public Offering consummated
on January 29, 2025, the Company sold 20,000,000 Units at a price of $10.00 per Unit. Each Unit consists of one ordinary share and one
right (“Public Right”), with each Public Right entitling the holder to receive one-eighth (1/8) of one ordinary share upon
the consummation of an initial business combination. In connection with the Initial Public Offering, the underwriters were granted a 45-day
option to purchase up to 3,000,000 additional Units to cover over-allotments, if any. On February 18, 2025, the underwriters exercised
their option to purchase an additional 3,000,000 Units at a purchase price of $10.00 per Unit, generating additional gross proceeds of
$30,000,000.

11

DRUGS MADE IN AMERICA ACQUISITION CORP.

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2025

(Unaudited)

NOTE 4 — PRIVATE PLACEMENT

Simultaneously with the closing of the Initial
Public Offering, the Company consummated the sale of 400,000 Private Placement Units at a price of $10.00 per Private Placement Unit in
a private placement to the Sponsor, for $4,000,000, of which $1,100,000 was not received and included as share subscription receivable.
Since the Initial Public Offering until March 31, 2025, the Sponsor has paid $247,621 in expenses on behalf of the Company reducing the
share subscription receivable on the una